Hansa Biopharma Logo

Hansa Biopharma

HNSA | XSTO

Overview

Corporate Details

ISIN(s):
SE0002148817 (+1 more)
LEI:
549300LLEO25ZJJ3NT91
Country:
Sweden
Address:
Box 785, 220 07 Lund
Sector:
Health Care
Industry:
Biotechnology

Description

Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That’s not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time. So how do we aim to achieve our goal? • We partner with global scientific, medical, and patient communities to identify the most urgent needs • We work relentlessly to meet the needs and create lifesaving treatments • Our lead program enables kidney transplantation in difficult-to-transplant patients

Social Media

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-05-26 18:40
Regulatory News Service
Hansa Biopharma plans restructuring to optimize resource allocation and improve…
English 220.5 KB
2025-05-26 18:40
Regulatory News Service
Hansa Biopharma planerar omstrukturering för att optimera resursfördelning och …
Swedish 204.8 KB
2025-05-26 07:00
Proxy Solicitation & Information Statements
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
English 206.6 KB
2025-05-26 07:00
General Meeting Notice
Kallelse till årsstämma i Hansa Biopharma AB (publ)
Swedish 461.9 KB
2025-04-24 08:00
Interim Report
Swedish 1.8 MB
2025-04-24 08:00
Interim Report
English 1.6 MB
2025-04-24 07:00
Board/Management Change
Hansa Biopharma appoints new Chief Executive Officer
English 178.1 KB
2025-04-24 07:00
Board/Management Change
Hansa Biopharma utser ny VD
Swedish 185.4 KB
2025-03-21 15:01
Annual Report
Swedish 2.2 MB
2025-03-21 15:01
Annual Report
English 2.2 MB
2025-02-06 07:00
Annual Report
Swedish 1.6 MB
2025-02-06 07:00
Annual Report
English 1.4 MB
2024-12-17 21:40
Earnings Release
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 stu…
English 162.0 KB
2024-12-17 21:40
Earnings Release
Hansa Biopharma meddelar positiva fullständiga resultat från fas 2-studien 15-H…
Swedish 222.7 KB
2024-10-17 07:00
Earnings Release
Swedish 1.6 MB

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-17 Anne Säfström Lanner Other Sell 2,685 134,223.15 SEK
2022-06-17 Donato Spota Other Sell 4,638 231,853.62 SEK
2022-06-17 Donato Spota Other Buy 10,311 N/A
2022-05-20 Christian Kjellman Other Buy 3,300 208,197.00 SEK
2022-04-26 Anne Säfström Lanner Other Buy 1,000 58,150.00 SEK
2022-03-16 Klaus Lykke Sindahl Other Buy 3,000 174,000.00 SEK
2021-11-09 Vincenza Nigro Other Buy 2,000 184,800.00 SEK
2021-07-16 Ulf Wiinberg Other Buy 10,000 1,122,200.00 SEK
2021-07-16 Soren Tulstrup Other Buy 2,000 222,371.35 SEK
2021-05-11 Klaus Lykke Sindahl Other Buy 1,200 168,900.00 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC